



# Synthesis of pentafluorosulfanyl (SF<sub>5</sub>) containing aromatic amino acids

Lucas Grigolato, William D.G. Brittain, Alex S. Hudson, Maria M. Czyzewska, Steven L. Cobb\*

Department of Chemistry, Durham University, South Road, Durham, DH1 3LE, United Kingdom



## ARTICLE INFO

### Keywords:

Amino acid  
Pentafluorosulfanyl  
SF<sub>5</sub>  
Negishi cross-coupling

## ABSTRACT

Herein, a series of aromatic pentafluorosulfanyl (SF<sub>5</sub>) containing amino acids are reported. A Negishi cross-coupling strategy utilising a catalyst system of Pd(dba)<sub>2</sub> and SPhos afforded the aforementioned SF<sub>5</sub> amino acids in yields between 32% and 42%. Two dipeptides utilising both the amine and carboxylic functionalities of the synthesised SF<sub>5</sub> containing amino acids were prepared, demonstrating their compatibility with common amide/peptide coupling reagents and strategies.

## 1. Introduction

The synthesis of novel amino acids is an area of considerable interest as it offers a route to access not only previously inaccessible natural products but also to modulate the properties of peptides [1–3]. Furthermore, the ability to include additional functionality (e.g. NMR probes, handles for chemical modification or bioconjugation) within peptide sequences has led to increasing interest in the synthesis of unusual amino acids in areas such as medicinal chemistry [4] and drug discovery [5,6].

Fluorine atoms have been demonstrated to modulate the structure, stability and activity of peptides [7]. For example, Meng and Kumar demonstrated that introduction of fluorine atoms into antimicrobial peptides increased their bacteriostatic activity or improved their stability towards protease degradation [8]. Therefore, the ability for peptide chemists to be able to readily access amino acid building blocks containing fluorine atoms is of the upmost importance.

The pentafluorosulfanyl (SF<sub>5</sub>) functional group is a moiety which at present is difficult to introduce into peptide sequences even though it has garnered attention across many research areas. The steric bulk and electronics of the SF<sub>5</sub> group can modify both the conformation and chemical properties of a compound. This has led to the SF<sub>5</sub> group being utilised to develop new pharmaceuticals [9] and agrochemicals [10].

The SF<sub>5</sub> group has also been used as a substitute for the trifluoromethyl (CF<sub>3</sub>) group [11], however their physical and chemical properties differ quite considerably [12]. For instance, the geometry, the electron density profile, chemical/thermal stability and volume of the two groups are all very different. In addition due to their steric and electronic properties SF<sub>5</sub> groups have also been investigated as replacements for *tert*-butyl [13], halogen [9] and nitro [14] functionalities.

There are a variety of ways to access alkyl [15–18] and aryl [19–24] pentafluorosulfanyl compounds. Despite the advances in the utility and synthesis of SF<sub>5</sub> building blocks, the ability to introduce them into peptides has so far been limited [25]. To the best of our knowledge only one previous synthesis of an SF<sub>5</sub> amino acid has been disclosed. Welch and co-workers reported a six step synthesis of an SF<sub>5</sub> containing allyl glycine derivative **3** and further elaborated the amino acid into a heptapeptide (Scheme 1) [25].

In order to further explore the SF<sub>5</sub> group in the field of peptide chemistry, we targeted the synthesis of pentafluorosulfanyl phenylalanine derivatives. Herein, we report the first synthesis of SF<sub>5</sub> aromatic amino acids utilising a Negishi cross-coupling as a key C–C bond forming step.


## 2. Results and discussion

Negishi cross-coupling has been used to access a wide range of amino acids previously within the literature [26,27]. Therefore to begin with a halogenated amino acid precursor **4** was selected as one coupling partner for our Negishi strategy. The two enantiomers of the benzyl protected iodo cross-coupling partner were synthesised from the corresponding Boc protected serines as previously reported [28].

Next a Negishi cross-coupling reaction was carried out between iodo-alanine **4S** and commercially available 1-bromo-4-(pentafluorosulfanyl)benzene. Iodo-alanine **4S** was treated with 4 equivalents of zinc in dry DMF. The formed alkyl zinc species was reacted with 1-bromo-4-(pentafluorosulfanyl)benzene as the other coupling partner. The reaction was carried out with a tri(*o*-tolyl)phosphine (P(*o*-tol)<sub>3</sub>) ligand (10 mol%) and a Pd(dba)<sub>2</sub> catalyst (3 mol%). This gave a disappointing 8% yield of the desired cross-coupling product **6R** (Table 1 Entry 1). When 1-bromo-3-(pentafluorosulfanyl)benzene was employed


\* Corresponding author.

E-mail address: [s.l.cobb@durham.ac.uk](mailto:s.l.cobb@durham.ac.uk) (S.L. Cobb).



**Scheme 1.** Previously accessed SF<sub>5</sub> containing amino acid, Welch and co-workers [25].

**Table 1**  
Reaction optimisation of the key Negishi cross-coupling reaction.



Starting material	Ligand	Bromo-phenyl-SF <sub>5</sub>	Product	Yield (%) <sup>a</sup>
 4S	P( <i>o</i> -tol) <sub>3</sub>		6R	8 <sup>b</sup>
	P( <i>o</i> -tol) <sub>3</sub>		5R	26 <sup>b</sup>
 4R	SPhos		6R	38 <sup>b</sup>
	SPhos		5R	35 <sup>b</sup>
	SPhos		6S	42 <sup>c</sup>
	SPhos		5S	32 <sup>c</sup>

a) Refers to the isolated yield following flash column chromatography.

b) Reactions stirred at 50 °C for 5 h.

c) Reactions stirred at 50 °C for 3 h.

a yield of 26% of compound **5R** was obtained (Table 1 Entry 2). In an attempt to improve these yields the P(*o*-tol)<sub>3</sub> ligand was switched for SPhos. SPhos has been previously shown by Jackson and co-workers to improve the yields of Negishi cross-coupled products in the reaction between amido zinc species and aryl bromides [29].

The addition of SPhos showed a marked improvement in the yields of the cross-coupled products. The yield of **6R** was increased to 38% (Table 1 Entry 3) and **5R** was similarly increased to 35% (Table 1 Entry 4). The opposite enantiomer, **4R** was also exposed to the SPhos/Pd(dba)<sub>2</sub> mediated conditions garnering the SF<sub>5</sub> containing species **6S** and **5S** in 42% and 32% yield respectively (Table 1 Entries 5 and 6).

Compound **6S** was successfully crystallised through vapour diffusion of water and ethanol and a crystal structure was obtained (Fig. 1) [30]. The structure obtained for **6S** displayed an absolute configuration of *S* confirming our stereochemical assignment.

In order to demonstrate the compatibility of **5** and **6** with amide bond formation and in turn peptide synthesis we sought to form dipeptides with both of these synthesised pentafluorosulfonyl amino acids. In addition, we hoped that our choice of orthogonal protecting groups would mean that selective deprotection could be carried out without degradation of the amino acids occurring.

Boc deprotection of **5R** was carried out using standard TFA mediated reaction conditions. The deprotected amino acid was reacted directly with Boc-Ala-OH in the presence of PyBOP and *N*-methylmorpholine (NMM). The amide bond forming reaction proceeded

smoothly to garner the desired dipeptide **8** in a 71% yield, over the two steps (Scheme 2).

Next the benzyl protected amino acid **6R** was deprotected through hydrogenation with palladium on charcoal to give the corresponding methyl ester **9**, which was subsequently deprotected to the free carboxylic acid **10** using lithium hydroxide. This material was directly coupled with Boc-Ala-OH in the presence of PyBOP and NMM. This reaction afforded the dipeptide **11** in a 19% yield over 3 steps (Scheme 3).

### 3. Conclusion

We have demonstrated that SF<sub>5</sub> containing aromatic amino acids can be accessed through the Negishi cross-coupling of pentafluorosulfonyl aryl bromides with amido alkyl iodide species. The use of SPhos as a ligand for palladium helped to increase the yields for the cross-couplings. This methodology is to the best of our knowledge only the second disclosed route to an SF<sub>5</sub> containing amino acid and the first to yield an aromatic SF<sub>5</sub> amino acid. The synthesised aryl-SF<sub>5</sub> amino acids were shown to be compatible with standard amide/peptide bond coupling reagents and de-protection strategies. We are now exploring the application of the newly formed aromatic SF<sub>5</sub> amino acids in larger peptide sequences, as a means to modify their chemical and physical properties.





Fig. 1. Crystal structure of compound 6S.

Scheme 2. Formation of a dipeptide using SF<sub>5</sub> amino acid 5R.

## 4. Experimental

### 4.1. General

All starting materials and reagents were bought from commercial sources and used as received. <sup>1</sup>H NMR spectra were recorded at 400, 600 and 700 MHz using Bruker Avance III, Varian VNMR(S)-600 and Varian VNMR(S)-700 spectrometers. <sup>13</sup>C NMR spectra were recorded at 100, 151 and 176 MHz using Bruker Avance III, Varian VNMR(S)-600 and Varian VNMR(S)-700 spectrometers. <sup>19</sup>F NMR spectra were recorded at 376 MHz using a Bruker Avance III spectrometer. All coupling constants are reported in Hertz (Hz). In cases where it was required 2D NMR techniques were used to confirm compound identity. Chemical shifts are reported in ppm and are referenced to residual solvent peaks; CHCl<sub>3</sub> (<sup>1</sup>H 7.26 ppm, <sup>13</sup>C 77.0 ppm) and DMSO (<sup>1</sup>H 2.50 ppm, <sup>13</sup>C 39.5 ppm). Mass spectra were collected on a Waters TQD mass spectrometer and accurate mass spectra were collected on a Waters LCT Premier XE mass spectrometer. Optical rotations were measured with a Jasco P-1020 polarimeter at room temperature.


### 4.2. General method for Negishi cross-coupling

#### Procedure A:

Zinc dust (0.193 g, 2.95 mmol, 4.0 equiv.) was heated at 100 °C under vacuum for 30 min. A catalytic amount of iodine in dry DMF (0.5 mL) was added and heated at 70 °C under argon for 20 min. Iodo-alanine derivative **4** (0.300 g, 0.74 mmol, 1.0 equiv.) in dry DMF (0.5 mL) was added and the reaction mixture heated at 50 °C for 20 min. After this time the corresponding (Bromophenyl)sulfur pentafluoride (0.209 g, 0.74 mmol, 1.0 equiv.), Pd(dba)<sub>2</sub> (0.012 g, 3 mol%) and P(*o*-tol)<sub>3</sub> (0.022 g, 0.073 mmol, 0.1 equiv.) were added to the reaction mixture and the reaction mixture stirred at 50 °C for 5 h followed by 24 h at rt. The crude material was purified directly by flash column chromatography (SiO<sub>2</sub> 100:0 to 0:100 hexane:DCM).

#### Procedure B:

The reaction was carried out in the same manner as described in procedure A with P(*o*-tol)<sub>3</sub> replaced by SPhos (0.030 g, 0.074 mmol, 0.1 equiv.).

Scheme 3. Formation of a dipeptide using SF<sub>5</sub> amino acid 8R.

#### 4.3. Synthesis of benzyl (R)-2-((tert-butoxycarbonyl)amino)-3-(3-(pentafluoro-l6-sulfanyl)phenyl)propanoate 5R

Compound **5R** was synthesised according to the general Negishi cross-coupling procedures

Procedure A: 0.091 g, 26%

Procedure B: 0.122 g, 35%

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.61 (d, *J* = 8.5, 1H, ArH), 7.49 (s, 1H, ArH), 7.39–7.35 (m, 3H, ArH), 7.32–7.27 (m, 3H, ArH), 7.15 (d, *J* = 7.3, 1H, ArH), 5.14 (s, 2H, OCH<sub>2</sub>), 5.04 (d, *J* = 7.1, 1H, NH), 4.65 (app. q, *J* = 5.8, 1H, H<sub>α</sub>), 3.22 (dd, *J* = 13.8, 5.8, 1H, H<sub>β</sub>), 3.10 (dd, *J* = 13.8, 5.8, 1H, H<sub>β</sub>), 1.41 (s, 9H, Boc-CH<sub>3</sub>); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.2, 155.0, 154.1, 154.1, 154.0, 137.4, 135.0, 132.7, 128.9, 128.83, 128.81, 128.7, 127.1, 124.8, 124.7, 124.7, 80.4, 67.6, 54.3, 38.3, 28.4; <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ 84.56 (quint., *J* = 150.4, 1 F), 62.83 (d, *J* = 150.4, 4 F). HRMS ESI<sup>+</sup> Calculated for [M+H]<sup>+</sup> C<sub>21</sub>H<sub>25</sub>F<sub>5</sub>NO<sub>4</sub>S<sup>+</sup> = 482.1424 Found = 482.1443; [α]<sub>D</sub><sup>27</sup> = -18.76 (c = 1, CH<sub>2</sub>Cl<sub>2</sub>)

#### 4.4. Synthesis of benzyl (R)-2-((tert-butoxycarbonyl)amino)-3-(4-(pentafluoro-l6-sulfanyl)phenyl)propanoate 6R

Compound **6R** was synthesised according to the general Negishi cross-coupling procedure

Procedure A: 0.030 g, 8%

Procedure B: 0.135 g, 38%

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.57 (d, *J* = 8.3, 2H, ArH), 7.43 – 7.34 (m, 3H, ArH), 7.30 – 7.26 (m, 2H, ArH), 7.10 (d, *J* = 8.1, 2H, ArH), 5.19 (d, *J* = 12.1, 1H, OCH<sub>2</sub>), 5.09 (d, *J* = 12.1, 1H, OCH<sub>2</sub>), 5.03 (d, *J* = 8.1, 1H, NH), 4.65 (app. q, *J* = 6.7, 1H, H<sub>α</sub>), 3.17 (dd, *J* = 13.8, 6.0, 1H, H<sub>β</sub>), 3.07 (dd, *J* = 13.8, 6.0, 1H, β-H<sub>β</sub>), 1.41 (s, 9H, Boc-CH<sub>3</sub>); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.3, 155.0, 152.8, 140.2, 135.0, 129.8, 128.9, 128.8, 126.2, 126.1, 126.1, 80.4, 67.6, 54.2, 38.1, 28.4; <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ 84.74 (quint., *J* = 150.4, 1 F), 63.01 (d, *J* = 150.4, 4 F). HRMS ESI<sup>+</sup> Calculated for [M+H]<sup>+</sup> C<sub>21</sub>H<sub>25</sub>F<sub>5</sub>NO<sub>4</sub>S<sup>+</sup> = 482.1424 Found = 482.1433; [α]<sub>D</sub><sup>27</sup> = -10.36 (c = 1, CH<sub>2</sub>Cl<sub>2</sub>)

#### 4.5. Synthesis of benzyl (S)-2-((tert-butoxycarbonyl)amino)-3-(3-(pentafluoro-l6-sulfanyl)phenyl)propanoate 5S

Compound **5S** was synthesised according to the general Negishi cross-coupling procedure B with the following modification. The reaction was stirred for 3 h at 50 °C followed by 24 h at rt to give the product in a 32% (0.225 g) yield.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.61 (dd, *J* = 8.2, 2.2, 1H, ArH), 7.50 (s, 1H, ArH), 7.40–7.35 (m, 3H, ArH), 7.34–7.28 (m, 3H, ArH), 7.16 (d, *J* = 7.6, 1H, ArH), 5.14 (s, 2H, OCH<sub>2</sub>), 5.10 (d, *J* = 8.2, 1H, NH), 4.66 (app. q, *J* = 6.5, 1H, H<sub>α</sub>), 3.23 (dd, *J* = 13.9, 6.0, 1H, H<sub>β</sub>), 3.11 (dd, *J* = 13.9, 6.0, 1H, H<sub>β</sub>), 1.42 (s, 9H, Boc-CH<sub>3</sub>); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.2, 155.0, 154.2, 154.1, 153.9, 137.4, 135.0, 132.6, 128.9, 128.8, 128.7, 127.1, 124.7, 124.7, 124.7, 80.3, 67.5, 54.3, 38.2, 28.3; <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ 84.60 (quint., *J* = 149.8, 1 F), 62.84 (d, *J* = 149.8, 4 F); HRMS ESI<sup>+</sup> Calculated for [M+H]<sup>+</sup> C<sub>21</sub>H<sub>25</sub>F<sub>5</sub>NO<sub>4</sub>S<sup>+</sup> = 482.1424 Found = 482.1436; [α]<sub>D</sub><sup>27</sup> = +19.08 (c = 1, CH<sub>2</sub>Cl<sub>2</sub>)

#### 4.6. Synthesis of benzyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-(pentafluoro-l6-sulfanyl)phenyl)propanoate 6S

Compound **6S** was synthesised according to the general Negishi cross-coupling procedure B with the following modification. The reaction was stirred for 3 h at 50 °C followed by 24 h at rt to give the product in a 42% (0.300 g) yield.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.57 (d, *J* = 8.3, 2H, ArH), 7.39 – 7.34 (m, 3H, ArH), 7.30 – 7.26 (m, 2H, ArH), 7.10 (d, *J* = 8.2, 2H, ArH), 5.19 (d, *J* = 12.1, 1H, OCH<sub>2</sub>), 5.09 (d, *J* = 12.1, 1H, OCH<sub>2</sub>), 5.03 (d,

*J* = 8.1, 1H, NH), 4.65 (m, 1H, H<sub>α</sub>), 3.17 (dd, *J* = 13.8, 6.0, 1H, H<sub>β</sub>), 3.07 (dd, *J* = 13.8, 6.0, 1H, H<sub>β</sub>), 1.41 (s, 9H, Boc-CH<sub>3</sub>); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 171.3, 155.0, 152.8, 140.2, 135.0, 129.8, 128.9, 128.8, 126.2, 126.1, 126.1, 80.4, 67.6, 54.2, 38.1, 28.4; <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ 84.58 (quint., *J* = 156.8 Hz, 1 F), 62.97 (d, *J* = 156.8 Hz, 4 F); HRMS ESI<sup>+</sup> Calculated for [M+H]<sup>+</sup> C<sub>21</sub>H<sub>25</sub>F<sub>5</sub>NO<sub>4</sub>S<sup>+</sup> = 482.1424 Found = 482.1446; [α]<sub>D</sub><sup>27</sup> = +10.78 (c = 1, CH<sub>2</sub>Cl<sub>2</sub>)

Crystal data for **6S**: C<sub>21</sub>H<sub>24</sub>F<sub>5</sub>NO<sub>4</sub>S, *M* = 481.47, monoclinic, space group P 2<sub>1</sub>, *a* = 13.8424(11), *b* = 5.4800(5), *c* = 15.2791(12) Å, β = 113.218(3)°, *U* = 1065.15(15) Å<sup>3</sup>, *F*(000) = 500.0, *Z* = 2, *D*<sub>c</sub> = 1.501 mg m<sup>-3</sup>, μ = 0.224 mm<sup>-1</sup> (Mo-Kα, λ = 0.71073 Å), *T* = 120(1)K. 21,584 reflections were collected on a Bruker D8Venture (Photon100 CMOS detector, μ(S)-microsource, focusing mirrors, shutterless mode, 1° ω-scan) diffractometer yielding 5393 unique data (*R*<sub>merge</sub> = 0.0614). The structure was solved by direct method and refined by full-matrix least squares on *F*<sup>2</sup> for all data using SHELXTL and OLEX2 software [31,32]. All non-hydrogen atoms were refined with anisotropic displacement parameters; H-atoms were placed into calculated positions and refined in riding mode. Final w*R*<sub>2</sub>(*F*<sup>2</sup>) = 0.1651 for all data (385 refined parameters), conventional *R*<sub>1</sub>(*F*) = 0.066 for 4374 reflections with *I* ≥ 2σ, *GOF* = 1.075. The absolute configuration of the compound has been established by measurements of anomalous dispersion effects (Flack parameter (*x*) = 0.1(1), Hooft parameter (*y*) = 0.07(4)). Crystallographic data for the structure have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication CCDC-1837505.

#### 4.7. Synthesis of benzyl (R)-2-((S)-2-((tert-butoxycarbonyl)amino)propanamido)-3-(3-(pentafluoro-l6-sulfanyl)phenyl)propanoate 8

To a stirred solution of Boc-D-(3-SF<sub>5</sub>)-Phe-OBn (**5R**) (0.110 g, 0.23 mmol) in DCM (4 mL) was added TFA (4 mL) and the resulting solution was stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure and any residual TFA was removed by co-evaporation with ether. The recovered material was suspended in DCM (2 mL) and NMM (0.087 g, 0.86 mmol, 0.08 mL) added, the resulting solution was stirred for 5 min at rt. PyBOP (0.120 g, 0.23 mmol) and Boc-Ala-OH (0.044 g, 0.23 mmol) dissolved in DCM (2 mL) were then added and the reaction mixture left to stir for 15 h at rt. The reaction mixture was concentrated under reduced pressure and purified via column chromatography (100:0 to 0:100, hexane/EtOAc). Dipeptide **8** was afforded as a cream solid in a 71% (0.090 g) yield over 2 steps.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.61 (ddd, *J* = 8.3, 2.3, 1.0, 1H, ArH), 7.47 (t, *J* = 1.9, 1H, ArH), 7.40 – 7.34 (m, 3H, ArH), 7.34 – 7.27 (m, 3H, ArH), 7.18 (d, *J* = 7.6, 1H, ArH), 6.72 (s, 1H, NH), 5.13 (app s, 2H, Bn-CH<sub>2</sub>), 4.90 (app. q, *J* = 6.1, 1H, Phe (3-SF<sub>5</sub>)-H<sub>α</sub>), 4.84 (bs, 1H, NH), 4.16 (m, 1H, Ala-H<sub>α</sub>), 3.23 (dd, *J* = 14.0, 5.8, 1H, Phe (3-SF<sub>5</sub>)-H<sub>β</sub>), 3.16 (dd, *J* = 14.0, 5.8, 1H, Phe (3-SF<sub>5</sub>)-H<sub>β</sub>), 1.41 (s, 9H, Boc-CH<sub>3</sub>), 1.30 (d, *J* = 7.1, 3H, Ala-H<sub>β</sub>); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.6, 170.8, 155.6, 154.3, 154.1, 154.0, 137.2, 134.9, 132.7, 129.0, 128.8, 128.6, 126.9, 126.9, 126.8, 124.8, 124.8, 124.7, 80.4, 67.7, 53.2, 50.1, 37.8, 29.8, 28.4, 18.2; <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ 84.46 (quint., *J* = 149.9, 1 F), 62.79 (d, *J* = 149.9, 4 F); HRMS ESI<sup>+</sup> Calculated for [M+H]<sup>+</sup> C<sub>24</sub>H<sub>30</sub>F<sub>5</sub>N<sub>2</sub>O<sub>5</sub>S<sup>+</sup> = 553.1796 Found = 553.1797.

#### 4.8. Synthesis of methyl ((R)-2-((tert-butoxycarbonyl)amino)-3-(4-(pentafluoro-l6-sulfanyl)phenyl)propanoyl)-L-alanine 11

To a mixture of Boc-D-(4-SF<sub>5</sub>)-Phe-OBn (**6R**) (0.075 g, 0.16 mmol) and Pd/C 10 wt% under an inert atmosphere was added dry methanol (10 mL). The solution was stirred for 24 h under a positive pressure of hydrogen. The solution was concentrated under reduced pressure and the residue taken up in THF (1 mL). The resulting solution was cooled to 0 °C before addition of a solution of LiOH (0.014 g, 2 equiv.) in water

(0.5 mL), the reaction was stirred for 2 h at 0 °C. The reaction mixture was then concentrated under reduced pressure. The remaining solution was acidified to pH ≈ 3 with an aqueous solution of citric acid (10%w/v). The solution was extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with brine (5 mL), dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The recovered oil was dissolved in DCM (2 mL) and PyBOP (0.084 g, 1 equiv.) added, the resulting solution was stirred at room temperature. In a separate flask, NH<sub>2</sub>-Ala-OMe.HCl (0.023 g, 1 equiv.) was dissolved in DCM (2 mL), NMM (0.06 mL, 3 equiv.) added and the resulting solution stirred for 5 min. The two solutions were mixed together and stirred at room temperature for 86 h. The reaction mixture was concentrated under reduced pressure and the residue purified via column chromatography (100% hexane to 100% EtOAc) to afford dipeptide **11** as a cream solid in a 19% (0.015 g) yield over 3 steps.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.68 (d, *J* = 8.4, 2H, ArH), 7.31 (d, *J* = 8.4, 2H, ArH), 6.45 (d, *J* = 7.4, 1H, NH), 4.95 (br s, 1H, NH), 4.52 (app t, *J* = 7.2, 1H, Ala-H<sub>α</sub>), 4.41 (br s, 1H, SF<sub>5</sub>-Phe-H<sub>α</sub>), 3.74 (s, 3H, OCH<sub>3</sub>), 3.19 (dd, *J* = 14.0, 7.0, 1H, SF<sub>5</sub>-Phe-H<sub>β</sub>), 3.05 (dd, *J* = 14.0, 7.0, 1H, SF<sub>5</sub>-Phe-H<sub>β</sub>), 1.39 (s, 9H, CH<sub>3</sub>), 1.31 (d, *J* = 7.1, 3H, Ala-H<sub>β</sub>); <sup>13</sup>C NMR (176 MHz, CDCl<sub>3</sub>) δ 172.89, 170.00, 140.81, 129.67, 126.15, 55.21, 52.53, 48.02, 37.83, 29.67, 28.16, 18.11. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ 84.58 (quin., *J* = 156.8, 1F), 62.97 (d, *J* = 156.8, 4F). HRMS ESI<sup>+</sup> Calculated for [M+H]<sup>+</sup> C<sub>18</sub>H<sub>35</sub>F<sub>5</sub>N<sub>2</sub>O<sub>5</sub>S<sup>+</sup> = 477.1490 Found = 477.1483.

## Acknowledgments

We wish to acknowledge the Biotechnology and Biological Sciences Research Council [BB/P003656/1] for financial support (WDGB). We thank Dr. Dmitry S. Yufit for help in the collection of X-ray crystal data and solving of the reported crystal structure.

## References

- N. Colgin, T. Flinn, S.L. Cobb, Synthesis and properties of MIDA boronate containing aromatic amino acids: new peptide building blocks, *Org. Biomol. Chem.* 9 (2011) 1864–1870.
- A.M. Webster, C.R. Coxon, A.M. Kenwright, G. Sandford, S.L. Cobb, A mild method for the synthesis of a novel dehydrobutyryne-containing amino acid, *Tetrahedron* 70 (2014) 4661–4667.
- T.S. Young, P.G. Schultz, Beyond the canonical 20 amino acids: expanding the genetic lexicon, *J. Biol. Chem.* 285 (2010) 11039–11044.
- M.A.T. Blaskovich, Unusual amino acids in medicinal chemistry, *Eur. J. Med. Chem.* 59 (2016) 10807–10836.
- A. Stevenazzi, M. Marchini, G. Sandrone, B. Vergani, M. Lattanzio, Amino acid scaffolds bearing unnatural side chains: an old idea generates new and versatile tools for the life sciences, *Bioorg. Med. Chem. Lett.* 24 (2014) 5349–5356.
- J. Vagner, H. Qu, V.J. Hruby, Peptidomimetics, a synthetic tool of drug discovery, *Curr. Opin. Chem. Biol.* 12 (2008) 292–296.
- E.N.G. Marsh, Fluorinated proteins: from design and synthesis to structure and stability, *Acc. Chem. Res.* 47 (2014) 2878–2886.
- H. Meng, K. Kumar, Antimicrobial activity and protease stability of peptides containing fluorinated amino acids, *J. Am. Chem. Soc.* 129 (2007) 15615–15622.
- J.M. Coteron, M. Marco, J. Esquivias, X. Deng, K.L. White, J. White, M. Koltun, F. El Mazouni, S. Kokkonda, K. Katneni, R. Bhamidipati, D.M. Shackleford, I. Angulo-Barturen, S.B. Ferrer, M.B. Jiménez-Díaz, F.-J. Gamó, E.J. Goldsmith, W.N. Charman, I. Bathurst, D. Floyd, D. Matthews, J.N. Burrows, P.K. Rathod, S.A. Charman, M.A. Phillips, Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential, *Eur. J. Med. Chem.* 54 (2011) 5540–5561.
- D.S. Lim, J.S. Choi, C.S. Pak, J.T. Welch, Synthesis and herbicidal activity of a pentafluorosulfanyl analog of trifluralin, *J. Pest Sci.* 32 (2007) 255–259.
- P.W. Chia, S.C. Brennan, A.M.Z. Slawin, D. Riccardi, D. O'Hagan, Allosteric agonists of the calcium receptor (CaR): fluorine and SF<sub>5</sub> analogues of cinacalcet, *Org. Biomol. Chem.* 10 (2012) 7922–7927.
- P.R. Savoie, J.T. Welch, Preparation and utility of organic pentafluorosulfanyl-containing compounds, *Chem. Rev.* 115 (2015) 1130–1190.
- B. Stump, C. Eberle, W.B. Schweizer, M. Kaiser, R. Brun, R.L. Krauth-Siegel, D. Lentz, F. Diederich, Pentafluorosulfanyl as a novel building block for enzyme inhibitors: trypanothione reductase inhibition and antiprotozoal activities of diarylamines, *ChemBioChem* 10 (2009) 79–83.
- A.O. Adeniji, B.M. Twenter, M.C. Byrns, Y. Jin, M. Chen, J.D. Winkler, T.M. Penning, Development of potent and selective inhibitors of ald-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure–activity relationships, *Eur. J. Med. Chem.* 55 (2012) 2311–2323.
- S.C. Ngo, J.H. Lin, P.R. Savoie, E.M. Hines, K.M. Pugliese, J.T. Welch, Preparation and reactions of aliphatic 2-pentafluorosulfanyl aldehydes, *Eur. J. Org. Chem.* 2012 (2012) 4902–4905.
- P.R. Savoie, S. Higashiyama, J.-H. Lin, D.V. Wagle, J.T. Welch, Conformational impact of pentafluorosulfanylation on acyclic aliphatic molecules, *J. Fluor. Chem.* 143 (2012) 281–286.
- A.-L. Dreier, A.V. Matsnev, J.S. Thrasher, G. Haufe, New approach to α-pentafluorosulfanyl-substituted carboxylic acid derivatives via Ireland–Claisen rearrangements, *J. Fluor. Chem.* 167 (2014) 84–90.
- P. Dudziński, A.V. Matsnev, J.S. Thrasher, G. Haufe, Synthesis of SF<sub>5</sub>CF<sub>2</sub>-containing enones and instability of this group in specific chemical environments and reaction conditions, *J. Org. Chem.* 81 (2016) 4454–4463.
- P. Beier, T. Pastýřiková, Hydroxylation of nitro-(pentafluorosulfanyl)benzenes via vicarious nucleophilic substitution of hydrogen, *Tetrahedron Lett.* 52 (2011) 4392–4394.
- P. Beier, T. Pastýřiková, G. Iakobson, Preparation of SF<sub>5</sub> aromatics by vicarious nucleophilic substitution reactions of nitro(pentafluorosulfanyl)benzenes with carbanions, *J. Org. Chem.* 76 (2011) 4781–4786.
- P. Beier, T. Pastýřiková, N. Vida, G. Iakobson, SNAr reactions of nitro-(pentafluorosulfanyl)benzenes to generate SF<sub>5</sub> aryl ethers and sulfides, *Org. Lett.* 13 (2011) 1466–1469.
- P. Beier, T. Pastýřiková, Synthesis of SF(5)-containing benzisoxazoles, quinolines, and quinoxalines by the Davis reaction of nitro-(pentafluorosulfanyl)benzenes, *Beilstein J. Org. Chem.* 9 (2013) 411–416.
- G. Iakobson, M. Pošta, P. Beier, Synthesis of pentafluorosulfanyl-containing indoles and oxindoles, *Synlett* 24 (2013) 855–859.
- A.-L. Dreier, B. Beutel, C. Mück-Lichtenfeld, A.V. Matsnev, J.S. Thrasher, G. Haufe, Synthesis of α-(pentafluorosulfanyl)- and α-(trifluoromethyl)-substituted carboxylic acid derivatives by Ireland–Claisen rearrangement, *J. Org. Chem.* 82 (2017) 1638–1648.
- D.S. Lim, J.-H. Lin, J.T. Welch, The synthesis and characterization of a pentafluorosulfanylated peptide, *Eur. J. Org. Chem.* 2012 (2012) 3946–3954.
- W.D.G. Brittain, S.L. Cobb, Negishi cross-couplings in the synthesis of amino acids, *Org. Biomol. Chem.* 16 (2018) 10–20.
- I. Rilatt, L. Caggiano, R.F.W. Jackson, Development and applications of amino acid derived organometallics, *Synlett* 2005 (2005) 2701–2719.
- A.S. Hudson, L. Caron, N. Colgin, S.L. Cobb, A direct method for the synthesis of orthogonally protected furyl- and thienyl- amino acids, *Amino Acids* 47 (2015) 779–785.
- A.J. Ross, H.L. Lang, R.F. Jackson, Much improved conditions for the Negishi cross-coupling of iodoalanine derived zinc reagents with aryl halides, *J. Org. Chem.* 75 (2010) 245–248.
- The CIF file was deposited in the Cambridge Structural Data Base (CCDC) under the code: CCDC 1837505. Copies of the data can be obtained, free of charge, via [www.ccdc.cam.ac.uk](http://www.ccdc.cam.ac.uk).
- G. Sheldrick, A short history of SHELX, *Acta Cryst.* 64 (2008) 112–122.
- O.V. Dolomanov, L.J. Bourhis, R.J. Gildea, J.A.K. Howard, H. Puschmann, OLEX2: a complete structure solution, refinement and analysis program, *J. Appl. Crystallogr.* 42 (2009) 339–341.